Providing solutions for professionals working in reproductive medicine
Board Certified and Full Professor of Obstetrics and Gynecology at the University of Valencia; Adjunct Clinical Professor, Department of Ob/Gyn, Stanford University School of Medicine, CA; Scientific Director of Instituto Valenciano de Infertilidad (IVI) and IGENOMIX.
Since 1991, his basic and clinical research has contributed to the advance of Reproductive Medicine, specifically in the understanding of human endometrial receptivity, embryo viability, embryonic implantation and endometriosis. He discovered the relevance of the interleukin-1 system in embryonic implantation (Simon et al., JCEM 1993; 1994; Endocrinology 1994; BOR 2006). He demonstrated the deleterious effect of high hormonal levels in patients with high response to gonadotrophins thus modifying the established clinical practice (HR1995; Fertil Steril 1996; 1998). He pioneered the concept that human oocytes are affected in endometriosis (HR 1994; Fertil Steril 2000) thus changing the clinical practice in oocyte donation. He proposed a new embryo coculture system, now successfully used worldwide (JCEM 1996; Fertil Steril 2003). His basic research on endometrial receptivity led him to create and patent a customized array named endometrial receptivity array (ERA) for the molecular diagnosis of endometrial receptivity (Fertil Steril 2011, 2013). He has been awarded “Prize Jaime I 2011 in Medical Investigation” for his pioneering work in human endometrial receptivity disorders.
In an independent bibliometric analysis considering publications in Reproductive Biology between 2003 and 2005, Carlos Simon was identified as the 9th most productive author in the world (Gonzalez-Alcaide G et al., Fertil Steril 90:941-56,2008).
Since 2001, he has expanded his research into the field of stem cells, resulting in the derivation, characterization, and registration in the Spanish National Stem Cell Bank (BNLC) of ten human embryonic stem cell (hESC) lines. He derived the first two hESC in Spain (Fertil Steril 2005) and described a new system for freezing hESC in the absence of animal contaminants. He derived VAL-6M, the first line with a monogenic disorder (Myotonic Dystrophy Type I) in Spain. Also, he obtained the first two hESC lines without destroying the human embryo using blastomere biopsy and demonstrated the lack of genetic diversity in the most common used hESC in the world (Mosher JT et al. N Engl J Med 2010). Finally, he reported the identification and characterization of human endometrial stem cells (Cervelló et al., PLoS ONE. 2010, 2011, 2012).
As Principal Investigator, his work has been funded through 16 projects sponsored by the Spanish Government, 4 by the Valencian Government, including 2 PROMETEO (granted to prestigious scientists) and 16 projects by international organizations, American Universities and private companies.
Metrics: At ISI Web of Knowledge Prof. Carlos Simon is author of 348 publications in international peer-review journals, adding up to an accumulated impact factor of 1,541.47. His papers have received a total of 11,139 cites with an average of 32 cites/paper. His H-Index is 60 and he is editor of 15 books. He has been Director of 28 PhD Thesis all qualified with “Cum Laude”, including 4 PhD Awards of Excellence and 3 European PhD. As inventor, his research has originated 13 Patent Applications, leading to the creation of IGENOMIX a biotech company.
As inventor, his research has originated 13 Patent Applications, leading to the creation of IGENOMIX a biotech company.
David earned a major in Business Science and an MBA from ESADE Business School. He is specialized in International Finance, with over 15 years of experience in consumer goods industries and 8 years in the health care industry. He has developed most of his career internationally, both in Europe and in America, working in Switzerland, US, Mexico and Spain.
He is an executive with broad private and public company backgrounds in both emerging and Fortune 500 companies. During his career, he has hold different responsibilities in Marketing, Finance, Business Development and IT providing him a wide view of business. David has been in general management for the last 8 years. He speaks fluent Spanish, English and French.
Since 2011, he has been the CEO of IGENOMIX, one of the leading companies in providing professional services in advanced molecular diagnoses in the reproductive medicine field.
Business Development Director Middle East & India
Francisco earned his MBA from IE Business School, Madrid and has a high degree in Industrial Engineering from Universidad de Navarra, Spain. He has over 12 years of experience and developed most of his career internationally.
Before joining Igenomix, he began his carrier working for PWC consulting company for more than 4 years, and then started helping leading companies in its internationalization process, establishing new subsidiaries and business units in Europe (Italy, France and Germany), US (California), and Asia (India, Japan and China). He has hold different responsibilities related to Planning and Finance, Business Strategy, Business Development and Marketing, providing him a wide view and experience. He speaks fluent Spanish and English.
For the last years, he has been the Business Developer Director for Asia and CEO of the recently launched subsidiary in India at IGENOMIX, one of the leading companies in providing professional services in advanced molecular diagnoses in the reproductive medicine field. Company belonging to the IVI Group.
Dr. Rajni Khajuria completed her Masters in Human Genetics in 2003 from Guru Nanak Dev University, Amritsar, Punjab. After completing her Masters, she joined the field of research and diagnostics in All India Institute of Medical Sciences (AIIMS), New Delhi, which is the Primary tertiary care hospital of India. She completed her Ph.D from AIIMS in year 2011 in the field of Molecular genetics, from Department of Pediatrics, under the supervision of Dr. Madhulika Kabra, one of the leading expert in the field of Pediatric Genetics in India.
Her doctorate research work has been involved in establishing the molecular diagnosis of Rett syndrome in India which facilitated the possibility of Prenatal Diagnosis and genetic counseling services for the families of Children affected with this unique disorder. She has been the Founder and National Scientific Adviser of “Indian Rett syndrome foundation”, the first national trust for the care and support of Indian families having children with Rett syndrome and also initiated the Awareness raising campaigns for Rett syndrome in India to educate the parents/Doctors/Healthcare professionals/Care givers/Scientists and Therapist, who were really unaware of this disorder.
While working in AIIMS for ~9.5 years, she was involved in Research and Diagnostics of various Pediatric genetic disorders as well as activities like teaching, trainings and organisation of various symposiums, conferences, workshops and Awareness programs. She has published and reviewed various peer review journals and has presented her research in several national and international conferences. She has been recipient of many awards and honors during her academic period. She is also a member of Indian society of Human Genetics and Genetic chapter, Indian Academy of Pediatrics.
She joined Igenomix India in May,2013 as a biologist to learn and take the advanced techniques of Preimplantation genetics like PGS and PGD further in India, and help all those Indian families who were deprived of these technologies previously and give them an option to have a healthy baby at home.
Dr. Brinderjit Singh completed his Ph.D. (2014) under the joint supervision of Prof. Prabhjeet Singh (GNDU, Amritsar) and Prof. Paramjit Khurana (UDSC, New Delhi), pioneers in the field of molecular biology. Dr. Brinderjit was able to demonstrate about the remarkable role(s) of two genes (TaVAP and TaeIF3g) in conferring tolerance to different abiotic stresses, validated in model systems, S. cerevisiae and A. thaliana.
Dr. Brinderjit worked as a Research Biologist in a project funded by Directorate of Forensic Sciences, New Delhi. In that project Dr. Brinderjit developed markers for the purity of different ingredients in the Dasamula Drug.
During his M.Sc.(Hon.) dissertation at Department of Human Genetics, Guru Nanak Dev University, Amritsar, he worked on a project entitled “DNA Damage Studies and SNP Analysis of Candidate Genes in Indian Psoriasis Patients”.
He has over 9.5 years of experience in the field of molecular biology. He joined Igenomix as a biologist in February, 2016. He has published many articles in peer-reviewed journals.
Lab Manager ERA
Maria Ruiz received her Bachelor degree in Biology at Murcia University (Spain). Maria Ruiz has over 4 years of clinical and research laboratory experience at IGENOMIX (Spain) as product manager of Endometrial Receptivity Array test (ERA) and as lab manager of the ERA laboratory. In her research, Maria Ruiz has been published in scientific journals as Fertility and Sterility and BBA-Molecular Basis of Disease.
Product Development Director
David Blesa is Doctor in Biological Sciences by the Department of Genetics at the University of Valencia in Spain. Currently Dr. Blesa is the Head of the Product Development Department at IGENOMIX.
From 2011 until 2013 he has been Head of Research & Development at the IVI Foundation and also Head of the Product Development Department at IGENOMIX S.L.
From 2006 to 2011 he was Researcher and Head of the Genomics Core Facility at the ‘Principe Felipe Research Centre’ (CIPF) in Valencia, Spain. Previously, since 2000, he worked in the field of cancer genetics first as Postdoctoral Fellow at the ‘Hospital Clínico Universitario’ in Valencia and at the ‘Spanish National Cancer Research Centre’ (CNIO) in Madrid and later as a Researcher at the CNIO within the Molecular Cytogenetics Group until 2006.
His main interest is centered in the field of genetics and genomics of human health and specifically in reproductive health. He has been principal researcher in projects financed by the Valencian and the Spanish Science and Innovation Governmental Office and is author in more than 25 research papers published in international journals and author in several book chapters.
Medical Research Manager
Medical Doctor and PhD in Obstetrics and Gynecology. She obtained her master’s degree in Human Reproduction at Valencia University, and performed two postdoctoral research trainings as embryologist and Reproductive endocrinologist at IVI Valencia and as postdoctoral Research fellow at Stanford University, California.
Her PhD Thesis entitled “Effect of high estradiol levels on embryo implantation in patients undergoing IVF”, contributed to the knowledge about concepts on endometrial receptivity and “mild stimulation” and was awarded by the University of Valencia and by the Medical college of Valencia.
She has worked as embryologist, Doctor and basic researcher in human reproduction field for more than 20 years enrolled at IVI Madrid, IVI Valencia and as Researcher at the Valencia Stem Cell Bank In the Centro de Investigación Príncipe Felipe, Valencia where she achieved the derivation, characterization, publication and registraty of first human embryonic stem cell lines in Spain deposited at Valencia Stem Cell Bank, as well as the development of a new animal-free cryopreservation system for stem cells (Valbuena et al, RBMonline 2008).
Her research has focused on human embryonic implantation, uterine receptivity and embryonic stem cells, leading to the publication of more than 50 peer-reviewed papers, many books chapters, as well as lectures as invited speaker at conferences worldwide. She has participated in 7 competitive funded research projects.
She had received awards from the American Fertility Society in 1997 and the Spanish Society of Obstetrics and Gynecology in 1998, among others, and is Professor of Masters related to Obstetrics and Gynecology, Reproductive Medicine and embryonic Stem Cells.
Product Development Manager
Dr. Antonio Díez-Juan PhD in Biology with honors in his class awarded by the University of Valencia. He developed his doctoral thesis at the Higher Council for Scientific Research (CSIC) on the molecular crosstalk between cell proliferation, aging and atherosclerosis.
After completing his doctoral thesis he worked five years as a postdoctoral scientist at the prestigious Center for Gene Therapy (VIB) at the University of Leuven in Belgium, discovering key mechanisms in different vascular processes such as: Arteriosclerosis, Angiogenesis, Ischemia and Development. After this period he worked in the National Centre for Cardiovascular Research (CNIC) in Madrid, Spain. At this time he began his career as an independent investigator working in the genetic control of organ regeneration. In September 2010 he move to Prince Felipe Research Centre. He founded a laboratory dedicated to identify molecular mechanisms modulating aging and metabolism in reproductive aging and diabetes.
Actually he works in Igenomix as a product innovation leadership. Now he is applying all his knowledge in molecular technology and biology to develop new products in advance reproductive genetics. He is the author of several research works in molecular biology.
His works have been published in high impact journals such as Nature Genetics, Cancer Cell, Blood, Circulation Research. In its little more than 10 year career builds an index h 19 and i10 index of 22 and more than 1400 citations.
More information is available through:
Dr. Inmaculada Moreno received her Bachelor degree and Ph.D. in Biochemistry at University of Valencia (Spain). She was awarded “Special doctorate prize” for her Ph.D. work.
She has more than 8 years of professional experience in the field of molecular biology. She has focused her research in human embryonic stem cells and induced pluripotent stem cells. Her academic activity is developed in several masters at University of Valencia (Spain) and the Polytechnic University of Valencia (Spain).
She has published 17 scientific papers in renowned journals as Cell Research, Human Molecular Genetics, Genes and Development or Stem Cells, and has participated in 30 national and international congresses. She has taken part in 4 international projects of scientific research.
In 2014, Dr. Moreno joined the Department of Research and Development at Igenomix where she develops basic and translational research projects in the field of reproductive medicine.